
Loading, please wait...

Loading, please wait...

Evaluating late-onset cerebellar ataxia presents a formidable diagnostic challenge for neurologists worldwide. Clinicians frequently encounter complex diagnostic dilemmas when distinguishing between neurodegenerative conditions. Specifically, RFC1-related ataxia and multiple system atrophy cerebellar type share extensive symptomatic overlap, including cerebellar dysfunction, autonomic instability, and extrapyramidal signs. However, an accurate diagnosis is essential for prognostic counseling and clinical management. A recent prospective multimodal study evaluated patients presenting with late-onset cerebellar ataxia to identify clear discriminative markers and longitudinal survival outcomes.
Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome arises from biallelic intronic AAGGG pentanucleotide repeat expansions in the replication factor C subunit 1 gene. Although classical presentations exhibit the complete triad, many individuals present with incomplete or atypical phenotypes. Consequently, these atypical variants frequently mimic multiple system atrophy cerebellar type. Both conditions manifest with progressive gait ataxia, speech impairment, limb dysmetria, and oculomotor dysfunction. Moreover, both neurodegenerative disorders may exhibit prominent dysautonomia, parkinsonism, and pyramidal signs during their disease course.
Because autonomic dysfunction and parkinsonian features can occur in both entities, clinicians often misclassify these patients during the initial stages. Nevertheless, differentiating these syndromes remains vital because their underlying pathophysiology and trajectories diverge considerably. Multiple system atrophy represents a rapidly progressive synucleinopathy characterized by widespread oligodendroglial cytoplasmic inclusions. In contrast, RFC1 repeat disorders involve primary sensory neuronopathy and slow neurodegeneration. Multimodal investigations, including detailed electrophysiology, autonomic testing, and advanced neuroimaging, provide indispensable insights into the precise diagnostic categorization.
The prospective multimodal study identified several robust clinical indicators that differentiate both disorders effectively. Patients diagnosed with RFC1-related ataxia typically demonstrate an earlier age at disease onset compared to those with multiple system atrophy cerebellar type. Furthermore, the onset of severe parkinsonian features, disabling autonomic failure, and pyramidal syndrome occurs significantly later in the disease timeline. Therefore, a prolonged interval before autonomic collapse strongly favors an underlying repeat expansion.
In addition, sensory neuropathy and chronic spasmodic cough serve as pivotal diagnostic clues. A history of unexplained, chronic dry cough often precedes motor balance impairment by several years or decades. Moreover, nerve conduction studies reveal widespread sensory axonal neuronopathy with absent or severely attenuated sensory nerve action potentials in nearly all affected individuals. Conversely, multiple system atrophy typically preserves sensory nerve conduction parameters. Bilateral vestibular areflexia on video head impulse testing further solidifies the suspicion of repeat expansion. Consequently, clinicians must systematically test vestibular function and sensory nerve action potentials in every patient presenting with late-onset cerebellar ataxia.
Neuroimaging plays an integral role in distinguishing these neurodegenerative syndromes during clinical workups. Brain magnetic resonance imaging in multiple system atrophy cerebellar type characteristically shows prominent pontine atrophy, middle cerebellar peduncle hyperintensities, and the distinctive hot cross bun sign. In contrast, magnetic resonance imaging in patients harboring pathogenic repeat expansions predominantly reveals cerebellar vermian and hemispheric atrophy with relative preservation of pontine volume.
Electrophysiological assessments provide immediate diagnostic distinction between these two entities. Routine nerve conduction studies consistently demonstrate non-length-dependent sensory neuronopathy in expansion carriers, whereas motor nerve parameters remain largely unaffected. Furthermore, vestibular testing through caloric stimulation and rotational chair assessment confirms bilateral horizontal semicircular canal hypofunction. In addition, autonomic reflex screening reveals marked differences in the timing and severity of cardiovascular autonomic failure. While multiple system atrophy rapidly causes severe orthostatic hypotension and early urogenital failure, autonomic impairment in repeat expansion carriers evolves slowly over decades. Hence, multimodal diagnostic algorithms drastically reduce diagnostic delays and prevent inappropriate invasive investigations.
Understanding disease trajectories is paramount for patient communication and life planning. The longitudinal analysis from the prospective cohort demonstrated distinct survival differences between the two patient groups. Specifically, multiple system atrophy cerebellar type progresses aggressively, leading to severe disability, wheelchair dependency, and death within a median of seven to nine years from symptom onset. Consequently, the rapid clinical decline creates tremendous caregiver burden and necessitates early palliative intervention.
Conversely, the disease course in expansion-related ataxia progresses at a significantly slower rate. The prospective study confirmed that median survival in expansion carriers exceeds twenty years following initial symptom onset. Although sensory ataxia and vestibular loss cause substantial imbalance and fall risks, functional independence persists for a markedly longer duration. Therefore, identifying this genetic etiology provides immense reassurance to patients who might otherwise fear an impending terminal diagnosis. Furthermore, accurate prognostic classification prevents unnecessary exposure to high-dose immunosuppressive therapies or misplaced experimental trials designed specifically for aggressive synucleinopathies.
These prospective multimodal findings emphasize the critical necessity of genetic screening in sporadic late-onset ataxia cohorts. Clinicians should maintain a high index of suspicion for RFC1 repeat expansions even when patients exhibit autonomic symptoms or mild parkinsonism. Whenever a patient presents with late-onset ataxia accompanied by sensory loss, chronic cough, or abnormal head impulse tests, physicians should immediately order targeted repeat expansion analysis.
Moreover, genetic confirmation carries profound ramifications for family counseling and risk assessment. Because the disease follows an autosomal recessive pattern of inheritance, the risk of recurrence among siblings is twenty-five percent, whereas the risk to offspring remains very low unless consanguinity exists. In addition, multidisciplinary management should focus on comprehensive vestibular rehabilitation, sensory substitution techniques, fall prevention strategies, and physiotherapy. Supportive measures for mild dysautonomia, such as compressive garments and fludrocortisone, effectively manage postural symptoms. Ultimately, adopting a standardized multimodal evaluation ensures timely diagnosis, tailored supportive therapy, and realistic long-term care planning.
Patients with RFC1-related ataxia typically experience symptom onset at an earlier age compared to multiple system atrophy cerebellar type. While symptoms often begin during middle adulthood in repeat expansion disorders, multiple system atrophy typically manifests later in life and progresses with much greater clinical rapidity toward motor disability.
Key clinical red flags include a chronic unexplained dry cough, profound sensory neuronopathy, and bilateral vestibular areflexia. Furthermore, the delayed appearance of dysautonomia and parkinsonism over decades contrasts sharply with the early, aggressive autonomic failure and motor decline seen in multiple system atrophy cerebellar type.
Genetic testing for RFC1 repeat expansions provides diagnostic certainty and prevents misdiagnosis as aggressive neurodegenerative synucleinopathies. Confirming an expansion reassures patients regarding a longer median survival exceeding twenty years, guides accurate familial recurrence counseling, and helps clinicians establish tailored physical and vestibular rehabilitation strategies.
Disclaimer: This content is for informational and educational purposes only. It is not intended to serve as medical advice, clinical guidance, or diagnostic instruction. Healthcare professionals should exercise independent clinical judgment and consult relevant clinical guidelines and expert recommendations. Refer to the latest local and national guidelines for clinical practice.
References
1. Pei I et al. Does CANVAS mimic MSA-C? A prospective multimodal study. J Neurol. 2026 Aug 19. doi: 10.1007/s00415-026-14005-7. PMID: 42616133.
2. Cortese A et al. Biallelic expansion in RFC1 is a common cause of late-onset ataxia and CANVAS. Nat Genet. 2019;51(4):649-658.
3. Gilman S et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670-676.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A prospective multimodal study evaluates sporadic late-onset cerebellar ataxia, distinguishing RFC1-related ataxia (CANVAS) from MSA-C. Key findings reveal that RFC1 cases present with earlier onset, sensory neuropathy, chronic cough, slower disease progression, and a median survival exceeding 20 years.
2 months ago

AIIMS New Delhi is establishing a real-time digital surveillance network to track acute toxicities nationwide. Upgrading the National Poisons Information Centre into a nodal research hub, this initiative introduces central antidote banking, analytical testing, and AI-assisted clinical decision support for clinicians.
Today

Public health experts urge policymakers to review rigorous clinical evidence before scaling up double fortified salt. With only half of India's anaemia cases stemming from iron deficiency, specialists highlight structural trial limitations, dietary diversity needs, and pending data from the SAMPADA national survey.
Today

A multicenter registry of 854 patients shows that re-isolating multiple reconnected pulmonary veins during second catheter ablation significantly lowers atrial arrhythmia recurrence, particularly in patients without heart failure, whereas extra-PV ablation provided no clear additive benefit.
Today

A clinical overview of resveratrol supplementation in mitigating exercise-induced muscle damage. This narrative review explores physiological mechanisms, reductions in soreness markers like creatine kinase, dosage strategies, and bioavailability enhancements for sports medicine and nutrition practitioners.
Today

The global APEX-T2D umbrella review synthesises data from over 200 million individuals, establishing that long-term PM2.5 exposure raises type 2 diabetes risk by 10% to 16% per 10 ug/m3. Clinicians must recognize ambient air pollution as an independent systemic metabolic disruptor alongside traditional risk factors.
Today